<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32558597</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5-6</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>A multi-center study of neurofilament assay reliability and inter-laboratory variability.</ArticleTitle><Pagination><StartPage>452</StartPage><EndPage>458</EndPage><MedlinePgn>452-458</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1779300</ELocationID><Abstract><AbstractText><i>Objectives</i>: Significantly elevated levels of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) have been described in the blood and cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis (ALS) patients. The aim of this study was to evaluate the analytical performance of different neurofilament assays in a round robin with 10 centers across Europe/U.S. <i>Methods</i>: Serum, plasma and CSF samples from a group of five ALS and five neurological control patients were distributed across 10 international specialist neurochemical laboratories for analysis by a range of commercial and in-house neurofilament assays. The performance of all assays was evaluated for their ability to differentiate between the groups. The inter-assay coefficient of variation was calculated where appropriate from sample measurements performed across multiple laboratories using the same assay. <i>Results</i><b>:</b> All assays could differentiate ALS patients from controls in CSF. Inter-assay coefficient of variation of analytical platforms performed across multiple laboratories varied between 6.5% and 41.9%. <i>Conclusions</i><b>:</b> This study is encouraging for the growing momentum toward integration of neurofilament measurement into the specialized ALS clinic. It demonstrates the importance of 'round robin' studies necessary to ensure the analytical quality required for translation to the routine clinical setting. A standardized neurofilament probe is needed which can be used as international benchmark for analytical performance in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oeckl</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amador</LastName><ForeName>Maria D M</ForeName><Initials>MDM</Initials><AffiliationInfo><Affiliation>Salpetriere Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Jiyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Iron Horse Diagnostics, Inc, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Iron Horse Diagnostics, Inc, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Schaepdryver</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslegrave</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhle</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Hospital and University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maceski</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Hospital and University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koel-Simmelink</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amsterdam University Medical Centres, Vrije Universiteit, Amsterdam Neuroscience, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamari</LastName><ForeName>Foudil</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Salpetriere Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Salpetriere Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinacker</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Amsterdam University Medical Centres, Vrije Universiteit, Amsterdam Neuroscience, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeromin</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cohens Veterans Biosciences, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="Y">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007753" MajorTopicYN="N">Laboratories</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">neurofilament</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32558597</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1779300</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>